USPTO serial 87763013
NAVIO
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- JOHNSON, DANYTHE ELIZABETH HA
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NAVIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian R. Coleman
Brian R. Coleman PERKINS COIE LLP3150 PORTER DRIVEPALO ALTO, CA 94304UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagents and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products; providing personalized molecular tumor for each patient, namely, providing medical research information regarding personalized molecular tumor treatments; providing medical research and scientific research information in the field of oncology via the Internet; development of a personalized ctDNA (circulating tumor DNA) assay; molecular profiling for scientific research purposes; providing RNA expression analysis for scientific research purposes; providing standard diagnostics and comprehensive diagnostics, namely, oncology patient diagnostic services for scientific research purposes; providing personalized drug screening for oncology patients for medical research purposes; providing real-time therapeutic response monitoring for oncology patients for medical research purposes; providing crowdsourcing platform in the nature of providing online non-downloadable software for obtaining information and input into a take or project by enlisting the services of a large number of people; molecular profiling for providing comprehensive medical treatment programs involving drug therapy for providing medical research; providing a database in the field of oncology and featuring inputting and collection of data and information all for treatment and diagnosis purposes, namely, providing a computer database in the field of oncology for treatment and diagnosis purposes featuring technology that allows users to input and collect data and information | ACTIVE | — |
| 044 | Medical services in the field of oncology, nephrology; dispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services via a website, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; developing and managing comprehensive treatment programs involving drug therapy, namely, providing comprehensive medical treatment programs involving drug therapy for the treatment of cancer; physician support services in the nature of providing medical consultation in the dispensing of prescription drugs for persons with particular cancers; providing medical evaluations of patients to determine acceptability for participation in clinical trials; providing healthcare medical counseling, screening, diagnosis, prognosis, treatment, relapse, palliative, integrative medicine, survivorship information, namely, providing comprehensive medical treatment programs involving drug therapy, and other related medical information in the field of oncology; Health care services, namely, providing a database in the field of oncology information and featuring inputting and collection of data and information all for treatment and diagnosis purposes; healthcare consultation in the field of cancer treatment research, namely, advising patients on cancer treatment research studies in which they might participate for purposes of treating their conditions; providing an online searchable database in the fields of oncology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for personalized diagnosis, treatment and prevention of cancer; molecular profiling for providing comprehensive medical treatment programs involving drug therapy for providing medical treatment; providing RNA expression analysis for medical treatment and diagnosis; providing personalized immunotherapy; Medical services, namely, providing cancer diagnosis; providing standard diagnostics and comprehensive diagnostics, namely, providing standard and comprehensive medical testing for diagnostic purposes; medical services, namely, providing personalized drug screening; providing real-time therapeutic response monitoring for medical treatment and diagnostic purposes; provide individualized expert medical advice and diagnosis in the field of oncology; provide machine learning based medical treatment for cancer patients; providing personalized molecular tumor for each patient, namely, providing medical treatment in the nature of providing personalized molecular tumor for each patient for the treatment of cancer; molecular profiling for oncology treatment purposes; providing RNA expression analysis for oncology treatment purposes; providing standard diagnostics and comprehensive diagnostics, namely, oncology patient diagnostic services for medical treatment purposes; providing personalized drug screening for oncology patients for medical purposes; providing real-time therapeutic response monitoring for oncology patients for medical purposes; providing personalized drug screening for medical treatment and diagnostic purposes; provide machine learning based treatment in the nature of medical treatment and diagnostic purposes for cancer patients | ACTIVE | — |
| 045 | Physician support services in the nature of providing legal consultation in the dispensing of prescription drugs for persons with particular cancers; providing survivorship information in the field of oncology, namely, legal advice regarding survivorship; provide individualized expert legal advice and diagnosis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Navio Theragnostics, Inc.
- Other trademarks owned by Navio Theragnostics, Inc.
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named NAVIO
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 11, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 11, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 2, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 31, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jan 31, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 31, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 10, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 8, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 8, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 8, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 11, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 9, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 9, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 9, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 7, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 5, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 5, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 5, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 9, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 30, 2020 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Nov 13, 2020 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Oct 20, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 20, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 30, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 14, 2020 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Sep 14, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 3, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 3, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 3, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 3, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 15, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 15, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 12, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 12, 2020 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Aug 12, 2020 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Aug 12, 2020 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Feb 18, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 18, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 18, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 24, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 19, 2019 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jun 14, 2019 | ALIE | ASSIGNED TO LIE | — |
| Nov 29, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 29, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 29, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 8, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 7, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 7, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 8, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 8, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 8, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 30, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 31, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 23, 2018 | NWAP | NEW APPLICATION ENTERED | — |